9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock

9 Meters Biopharma, Inc. (NASDAQ: NMTR) announces proposed public offering of common stock

Intuitive Venture PartnersDecember 10, 20209 Meters, 2020

Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces FDA approval of IND application for EB613 – an oral human parathyroid hormone (1-34) for the treatment of osteoporosis

Intuitive Venture PartnersDecember 10, 2020entera bio, 2020

Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces completion of enrollment in phase 2 clinical trial of Eb613 In osteoporosis

Intuitive Venture PartnersNovember 9, 2020entera bio, 2020

Peernova Raises $31 Million in New Funding for Global Expansion

Peernova, an enterprise blockchain software startup that helps banks and financial institutions simplify reconciliation and other data processes, has raised $31 million in new funding.

Intuitive Venture PartnersOctober 24, 20192019, peernova

Angion Announces Strategic Additions to Management Team

Angion Biomedica Corp. (NASDAQ: ANGN) announces several strategic additions to its management team to support the future development and commercialization of ANG-3777

Intuitive Venture PartnersOctober 15, 20192019, angion

Angion Presents Late-Breaking Data on ANG-3777

Angion Biomedica Corp. (NASDAQ: ANGN) presents late-breaking data on ANG-377 in delayed graft function at the American Society of Nephrology Kidney Week 2019.

Intuitive Venture PartnersOctober 11, 20192019, angion

Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) to merge with RDD Pharma creating new gastroenterology company focused on specialty, rare and orphan diseases.

Intuitive Venture PartnersOctober 7, 2019innovate biopharmaceuticals, 2019

Entera Bio Reports Positive Results From a Phase 2 PK/PD Study

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) reports positive results from a phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism.

Intuitive Venture PartnersSeptember 23, 2019entera bio, 2019

HZO Inc. Raises $70 Million in New Financing

HZO Inc. announced today that it has closed on $70 million in a new financing round.

Intuitive Venture PartnersApril 23, 2019HzO, 2019

Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts Focusing on the Molecular Biology and Pharmacology of Larazotide for the 2019 Digestive Disease Week Conference

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced that three abstracts were accepted for presentations during the 2019 Digestive Disease Week (DDW) conference.

Intuitive Venture PartnersFebruary 25, 2019innovate biopharmaceuticals, 2019

Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute

Neurotrope, Inc. (NASDAQ: NTRP) announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1.

Intuitive Venture PartnersFebruary 4, 2019neurotrope, 2019

Entera Bio Announces Positive Feedback and Guidance from the US FDA

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to disscuss the Company’s development plan for Oral PTH for the treatment of osteoporosis.

Intuitive Venture PartnersJanuary 31, 2019entera bio, 2019

Angion Completes Equity Financing and Appoints Senior Executives

Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage clinical biopharmaceutical company focused on kidney diseases and other acute organ injuries, announces the recent closing of a $35 million equity private placement.

Intuitive Venture PartnersJanuary 4, 2019angion, 2019

Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses.

Intuitive Venture PartnersDecember 11, 2018entera bio, 2018

Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P.

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced today that Patrick H. Griffin, M.D., F.A.C.P. has joined as the acting head of clinical development.

Intuitive Venture PartnersNovember 26, 2018innovate biopharmaceuticals, 2018

Angion Biomedica and Sinovant Sciences Enter into Collaboration and License Agreement to Develop BB3 in Greater China

Angion Biomedica Corp. (NASDAQ: ANGN) and Sinovant Sciences today announced a collaboration and license agreement for BB3, which is shown to have improved renal function post-transplant.

Intuitive Venture PartnersNovember 12, 2018angion, 2018

Entera Bio Reports Positive Results from Study of Oral PTH in Patients with Hypoparathyroidism

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug.

Intuitive Venture PartnersNovember 8, 2018entera bio, 2018

Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference

Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT) announces it intends to present at the Jefferies 2018 London Healthcare Conference. The conference is being held on November 14-15, 2018.

Intuitive Venture PartnersOctober 31, 2018innovate biopharmaceuticals, 2018

HZO Inc. Acquires Semblant Ltd. to Accelerate Expansion of Protective Coating and Waterproofing Solutions for Electronic Device Manufacturers

HZO Inc. announced today that it has acquired Semblant Ltd., a U.K.-based leader in protective nano coatings and waterproof technology.

Intuitive Venture PartnersOctober 24, 20182018, HzO

Entera Bio Appoints Two New External Independent Members to the Board of Directors

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors, effective immediately.

Intuitive Venture PartnersOctober 2, 2018entera bio, 2018